DK1136075T3 - Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion - Google Patents

Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion

Info

Publication number
DK1136075T3
DK1136075T3 DK01113628T DK01113628T DK1136075T3 DK 1136075 T3 DK1136075 T3 DK 1136075T3 DK 01113628 T DK01113628 T DK 01113628T DK 01113628 T DK01113628 T DK 01113628T DK 1136075 T3 DK1136075 T3 DK 1136075T3
Authority
DK
Denmark
Prior art keywords
eradication
infection
patients
combination therapy
chronic hepatitis
Prior art date
Application number
DK01113628T
Other languages
Danish (da)
English (en)
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27130070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1136075(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/938,033 external-priority patent/US6172046B1/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1136075T3 publication Critical patent/DK1136075T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK01113628T 1997-09-21 1998-08-07 Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion DK1136075T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/938,033 US6172046B1 (en) 1997-09-21 1997-09-21 Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US93512397A 1997-09-22 1997-09-22

Publications (1)

Publication Number Publication Date
DK1136075T3 true DK1136075T3 (da) 2003-04-28

Family

ID=27130070

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98306332T DK0903148T3 (da) 1997-09-21 1998-08-07 Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion
DK01113628T DK1136075T3 (da) 1997-09-21 1998-08-07 Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98306332T DK0903148T3 (da) 1997-09-21 1998-08-07 Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion

Country Status (24)

Country Link
EP (3) EP0903148B1 (pt)
JP (1) JPH11152231A (pt)
KR (1) KR20010024188A (pt)
CN (1) CN1250283C (pt)
AR (1) AR013497A1 (pt)
AT (2) ATE230999T1 (pt)
AU (1) AU749924B2 (pt)
BR (1) BR9812484A (pt)
CA (1) CA2245938C (pt)
CO (1) CO4970691A1 (pt)
DE (2) DE69801970T2 (pt)
DK (2) DK0903148T3 (pt)
ES (2) ES2186660T3 (pt)
HK (2) HK1016505A1 (pt)
HU (1) HUP0100092A3 (pt)
IL (1) IL134428A0 (pt)
MY (1) MY117781A (pt)
NO (1) NO20001437D0 (pt)
NZ (1) NZ502740A (pt)
PE (1) PE119199A1 (pt)
PT (1) PT903148E (pt)
SK (1) SK3922000A3 (pt)
TW (1) TW568787B (pt)
WO (1) WO1999015194A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059621A1 (en) * 1998-05-15 1999-11-25 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
JP2003507322A (ja) * 1998-12-18 2003-02-25 シェリング・コーポレーション リバビリン−ＰＥＧ化インターフェロン−α誘発ＨＣＶ併用治療
WO2000037097A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
DE19919585A1 (de) 1999-04-29 2000-12-07 Cmi Ag Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
CA2747325A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US7053228B2 (en) 2000-09-18 2006-05-30 Applied Research Systems Ars Holding N.V. Sulfur analogues of 21-hydroxy-6,19-oxidoprogesterone (21OH-6OP) for treating excess of glucocorticoids
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
AP2005003213A0 (en) 2002-06-28 2005-03-31 Univ Cagliari 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
JP2004155777A (ja) * 2002-10-16 2004-06-03 Asahi Kasei Pharma Kk Ｃ型慢性肝炎治療剤
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
CN100503628C (zh) 2003-05-30 2009-06-24 法莫赛特股份有限公司 修饰的氟化核苷类似物
CN1835765A (zh) * 2003-08-13 2006-09-20 霍华德·J·史密斯及同仁控股有限公司 治疗病毒感染的方法
ES2245248B1 (es) * 2004-06-09 2007-02-16 Universidad De Salamanca Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos.
PL3109244T3 (pl) 2004-09-14 2019-09-30 Gilead Pharmasset Llc Wytwarzanie 2'fluoro-2'-alkilo-podstawionych lub innych ewentualnie podstawionych rybofuranozylopirymidyn i puryn oraz ich pochodnych
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN101820887A (zh) 2007-07-25 2010-09-01 拜奥雷克斯治疗公司 干扰素控释药品以及使用相同药品治疗hcv感染
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
CN102458470B (zh) 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
AU2011235044A1 (en) 2010-03-31 2012-11-22 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN105748499B (zh) 2013-01-31 2018-12-28 吉利德制药有限责任公司 两个抗病毒化合物的联用制剂
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection

Also Published As

Publication number Publication date
BR9812484A (pt) 2000-09-19
ATE230999T1 (de) 2003-02-15
HUP0100092A3 (en) 2002-03-28
EP0903148A2 (en) 1999-03-24
AR013497A1 (es) 2000-12-27
CN1271292A (zh) 2000-10-25
DK0903148T3 (da) 2001-12-17
IL134428A0 (en) 2001-04-30
CN1250283C (zh) 2006-04-12
NO20001437L (no) 2000-03-20
PE119199A1 (es) 1999-12-01
SK3922000A3 (en) 2000-10-09
DE69801970D1 (de) 2001-11-15
DE69810822T2 (de) 2003-11-20
WO1999015194A1 (en) 1999-04-01
NO20001437D0 (no) 2000-03-20
DE69801970T2 (de) 2002-06-13
HUP0100092A2 (hu) 2001-05-28
CA2245938C (en) 2003-07-15
CO4970691A1 (es) 2000-11-07
TW568787B (en) 2004-01-01
AU9473798A (en) 1999-04-12
HK1041440A1 (en) 2002-07-12
DE69810822D1 (de) 2003-02-20
NZ502740A (en) 2002-10-25
JPH11152231A (ja) 1999-06-08
HK1041440B (zh) 2003-09-05
EP0903148A3 (en) 1999-04-28
AU749924B2 (en) 2002-07-04
EP1136075A1 (en) 2001-09-26
EP1136075B1 (en) 2003-01-15
PT903148E (pt) 2002-02-28
EP1317929A3 (en) 2003-07-02
EP1317929A2 (en) 2003-06-11
ATE206618T1 (de) 2001-10-15
MY117781A (en) 2004-08-30
ES2162393T3 (es) 2001-12-16
ES2186660T3 (es) 2003-05-16
KR20010024188A (ko) 2001-03-26
HK1016505A1 (en) 1999-11-05
EP0903148B1 (en) 2001-10-10
CA2245938A1 (en) 1999-03-21

Similar Documents

Publication Publication Date Title
DK1136075T3 (da) Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
ZA988466B (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
ID29285A (id) PENGGUNAAN PEG-IFN-α DAN RIBAVIRIN UNTUK PENGOBATAN HEPATITIS C KRONIS
NO20005755L (no) Kombinasjonsterapi omfattende ribavirin og interferon-<alfa> hos antivirusbehandlingsnaive pasienter med kronisk hepatitt C- infeksjon
WO2002032414A3 (en) Ribavirin-pegylated interferon alfa hcv combination therapy
NO983410L (no) FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
MY133891A (en) Polyethylene glycol modified interferon therapy
BR0009840A (pt) Terapia de combinação para hcv, contendo ribavirina em associação com antioxidantes
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
NO20011789D0 (no) Ribavirin-interferon-<alfa>-kombinasjonsterapi for utryddelse av påvisbar HCV-RNA i pasienter med kronisk hepatitt C-infeksjon
EP1037974A4 (en) TRUNCATED PROTEIN OF HEPATITIS C VIRUS NS5B AND RELATED METHODS OF IDENTIFYING ANTIVIRAL COMPOUNDS
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
ATE220332T1 (de) Behandlung von hepatitis b mit thymosin alpha 1 und lamivudin
IL151033A0 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica